VVOS Vivos Therapeutics, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1716166 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY18.6%
TTM net income YoY-28.6%
TTM EPS YoY23.7%
Revenue 3-yr CAGR12.3%
Net income 3-yr CAGR—
Margins
Gross margin60.0%
Operating margin-105.8%
Net margin-107.2%
FCF margin-88.5%
EBITDA margin-96.2%
Returns
ROE-899.5%
ROA-90.7%
ROIC (approx.)-283.8%
Asset turnover0.85x
Leverage & solvency
Liabilities / assets90.5%
Debt / equity0.77x
Current ratio0.22x
Interest coverage-6.03x
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-24.1%
Payout ratio—
Capex / revenue9.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $6.41M | $5.15M | $5.14M | $3.82M | $6.78M | $3.82M | $3.02M | $3.70M |
| Cost of revenue | $3.10M | $2.20M | $2.08M | $836,000 | $2.85M | $1.71M | $1.51M | $1.60M |
| Gross profit | $3.31M | $2.95M | $3.06M | $2.99M | $3.94M | $2.11M | $1.51M | $2.10M |
| SG&A expense | $6.45M | $7.11M | $8.97M | $8.55M | $7.88M | $6.41M | $4.89M | $4.35M |
| Operating income | -$3.90M | -$4.83M | -$6.62M | -$6.38M | -$4.73M | -$4.87M | -$3.92M | -$2.81M |
| Interest expense | $600,000 | $1.10M | $1.10M | $800,000 | $500,000 | — | — | — |
| Pretax income | -$1.97M | -$5.52M | -$7.75M | -$6.95M | -$5.40M | -$5.01M | -$3.86M | -$2.83M |
| Net income | -$1.95M | -$5.48M | -$7.68M | -$6.89M | -$5.40M | -$5.01M | -$3.86M | -$2.83M |
| EBITDA | -$3.35M | -$4.32M | -$6.16M | -$5.94M | -$4.35M | -$4.56M | -$3.74M | -$2.66M |
| EPS (basic) | -0.07 | -0.31 | -0.52 | — | -0.49 | -0.55 | -0.45 | — |
| EPS (diluted) | -0.07 | -0.31 | -0.52 | — | -0.49 | -0.55 | -0.45 | — |
| Weighted avg. shares (diluted) | 26.53M | 17.68M | 14.63M | — | 10.96M | 9.09M | 8.60M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $247,000 | $1.77M | $2.11M | $2.03M | $3.09M | $4.40M | $2.34M | $6.26M |
| Receivables | $2.37M | $1.44M | $1.77M | $1.58M | $2.13M | $1.63M | $718,000 | $430,000 |
| Current assets | $3.51M | $4.21M | $4.82M | $4.38M | $5.79M | $6.73M | $3.61M | $7.47M |
| PP&E, net | $3.35M | $3.64M | $3.53M | $3.76M | $5.64M | $5.13M | $3.31M | $3.31M |
| Goodwill | $8.57M | $8.57M | $8.57M | $8.57M | $8.45M | $8.45M | $2.84M | $2.84M |
| Intangibles | $3.44M | $3.64M | $3.84M | $4.04M | $2.17M | $2.23M | $358,000 | $409,000 |
| Total assets | $22.86M | $24.14M | $25.04M | $25.15M | $25.64M | $26.03M | $11.28M | $15.28M |
| Current liabilities | $16.16M | $20.39M | $17.94M | $18.08M | $7.44M | $6.43M | $4.70M | $4.98M |
| Short-term debt | $1.50M | $7.77M | $7.30M | $8.35M | $339,000 | $157,000 | — | — |
| Long-term debt | $313,000 | $366,000 | $418,000 | $469,000 | $8.38M | $7.76M | — | $1.20M |
| Total debt | $1.81M | $8.14M | $7.72M | $8.82M | $8.72M | $7.92M | — | $1.20M |
| Total liabilities | $20.69M | $28.13M | $26.31M | $26.70M | $23.11M | $21.45M | $6.88M | $7.33M |
| Shareholders' equity | $2.36M | -$3.81M | -$1.14M | -$1.49M | $2.53M | $4.58M | $4.41M | $7.95M |
| Net debt | $1.57M | $6.36M | $5.61M | $6.79M | $5.63M | $3.52M | — | -$5.06M |
| Shares outstanding | 33.82M | 14.53M | 13.49M | 9.29M | 8.27M | 7.32M | 5.89M | 5.89M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.18M | -$3.15M | -$6.01M | -$3.81M | -$4.16M | -$3.49M | -$3.80M | -$2.94M |
| Capital expenditure | $61,000 | $416,000 | $18,000 | $1.53M | -$83,000 | $771,000 | $122,000 | $165,000 |
| Free cash flow | -$3.24M | -$3.56M | -$6.03M | -$5.34M | -$4.08M | -$4.26M | -$3.92M | -$3.10M |
| Investing cash flow | -$61,000 | -$416,000 | -$18,000 | -$1.58M | $83,000 | -$5.91M | -$122,000 | -$165,000 |
| Financing cash flow | $1.71M | $3.23M | $6.11M | $4.33M | $2.76M | — | — | $3.05M |
| Depreciation & amortization | $550,000 | $510,000 | $454,000 | $442,000 | $384,000 | $306,000 | $177,000 | $144,000 |
| Stock-based compensation | $100,000 | $100,000 | $151,000 | $47,000 | $100,000 | $300,000 | $317,000 | $57,000 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.